UNC part of national trial to study Moderna vaccine s impact on COVID-19 transmission dailytarheel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailytarheel.com Daily Mail and Mail on Sunday newspapers.
MedCity News
Startup Ozette unveils AI approach to understanding the immune system
Ozette applies artificial intelligence to immune monitoring to gain greater insight into a cancer patient s immune system. Beyond informing treatment decisions, the technology can guide drug and diagnostic development.
Shares1
Cancer patients receive a check-in to see how their immune cells are working and whether the disease is responding to treatment. This immune monitoring is a routine part of cancer care and it helps guide treatment decisions. Yet current analysis methods remain limited, according to Ali Ansary, co-founder and CEO of startup Ozette.
The Seattle-based company aims to take immune monitoring further and it is using artificial intelligence to do it. The approach could accelerate analysis of the immune system, helping clinicians make better diagnostic and treatment decisions. The technology could yield insights not only for cancer care, but also infectious disease, inflammato
Researchers have found that a new urine test is extremely accurate at detecting aggressive prostate cancer with few false negatives.
The test could have possibly avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study of more than 1,500 patients.
The MyProstateScore test measures levels of cancer-specific genes in a patient’s urine. It’s based on previous research that discovered half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together creating an on-switch for prostate cancer development.
E-Mail
A urine test based on University of Michigan Rogel Cancer Center research could have avoided one third of unnecessary prostate cancer biopsies while failing to detect only a small number of cancers, according to a validation study that included more than 1,500 patients. The findings appear in the March issue of the
Journal of Urology.
The MyProstateScore test, which is being commercialized by LynxDX, a U-M startup company, measures levels of cancer-specific genes in a patient s urine. It is based on U-M research that discovered that half of all prostate tumors harbor a certain genetic anomaly in which the genes TMPRSS2 and ERG relocate on a chromosome and fuse together creating an on-switch for prostate cancer development.
A nurse in personal protective equipment assists with a procedure on a Covid-19 patient in the ICU at Regional Medical Center in San Jose, Calif.
Justin Sullivan/Getty Images
As health officials in the United States announced a second and possibly a third person infected with a new, more transmissible strain of the SARS-CoV-2 virus, infectious diseases experts are feeling a sense of déjà vu all over again.
A little less than a year ago, the early response to the coronavirus crisis was stifled by an inability to scale up testing to detect the virus and curb its spread. Now, once again, it’s unclear how prevalent the new strain, which first surfaced in the U.K., might be in the U.S. Already a possible and a probable case have been detected in Colorado and one case has been reported in California. But it’s likely the variant’s spread hasn’t stopped there.